^
Association details:
Biomarker:MYC translocation + BCL2 translocation
Cancer:Diffuse Large B Cell Lymphoma
Regimen: (cyclophosphamide + doxorubicin hydrochloride + prednisone + Rituxan (rituximab) + vincristine)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

3762 Long-term outcomes for stage I-II diffuse large B-cell lymphoma treated with rituximab and chemotherapy with or without radiotherapy

Published date:
11/01/2020
Excerpt:
Seven cases were reclassified as high-grade B-cell lymphoma with translocations of MYC and BCL2...113 patients (62.8%) received rituximab-chemotherapy (median 5 cycles, IQR = 4-6 with R-CHOP for n = 92 [81.4%]) followed by RT...There was a significantly higher 8-year PFS, 79.9% vs. 58.2% (P<0.0001), and OS, 87.5 vs. 67.9% (P<0.0001), for mIPI 0-1 vs. mIPI >1, respectively....PFS and OS for patients with stage I-II DLBCL were excellent following rituximab-chemotherapy with or without RT for those who were low risk (mIPI 0-1).
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Clinical and Biological Features behind Hallmark Aberrations in Diffuse Large B-Cell Lymphoma

Published date:
11/01/2018
Excerpt:
CONTRADICTING EVIDENCE:...152 primary DLBCL patients treated with R-CHOP or R-CHOP-like regimen....Co-occurring MYC and BCL2/BCL6 translocations (Double hit lymphomas, DHL) were recognized in 5.6% cases, most of which were GCB DLBCLs with poor outcome (Figure 1D).
DOI:
10.1182/blood-2018-99-117958